On October 22, 2019 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body’s immune system to fight cancer, reported the acceptance of an abstract at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (Press release, Anixa Biosciences, OCT 22, 2019, View Source [SID1234542398]). A poster presentation will include data from ongoing studies utilizing Cchek, the company’s artificial intelligence (AI) driven cancer detection technology.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The SITC (Free SITC Whitepaper) meeting is being held November 6 – 10, 2019 in National Harbor, MD. Cutting-edge research will be presented by experts in the field of applied cancer immunotherapy and translational research. The meeting will be attended by both U.S. and international researchers, regulators, and healthcare professionals who are involved in cancer research and clinical care.
Poster presentation details are as follows:
Title: Early detection of breast cancer (BCa) through MDSC and lymphocyte immunophenotyping: from manual gating to pattern recognition neural networks
Authors: George A. Dominguez, Ph.D.; John Roop; Alex Polo; Anthony J. Campisi; Dmitry I. Gabrilovich, MD, Ph.D.; Amit Kumar, Ph.D.
Poster Number: P11
Location: Gaylord National Hotel & Convention Center; Poster Hall: Prince George AB
Date and Time: Friday, November 8, 2019 (12:30 – 2:00 PM ET and 6:30 – 8:00 PM ET)
To receive a copy of the presentation, please email your request to SITC (Free SITC Whitepaper)[email protected] starting November 10, 2019 and include your name, title, and contact information.
About Cchek
Cchek is an early cancer detection technology, which measures a patient’s immunological response to a malignancy by analyzing immune system cells in peripheral blood. The goal is to utilize the technology to determine a patient’s cancer status from a simple blood draw, eliminating the need for a biopsy, which can be an expensive, painful and invasive procedure. Further, conventional methods using current cancer screening tests often lack accuracy and reliability. Anixa’s orthogonal approach using flow cytometry coupled with artificial intelligence provides an alternative method with greater affordability, efficacy and efficiency. To date, Anixa has successfully used Cchek to detect the presence of 20 different cancers including lung, colon, breast and prostate. The robust cancer detection performance of Cchek makes it a platform from which multiple cancer diagnostic tests may be developed. The first such test, a prostate cancer confirmation test, is slated for commercial launch by the end of 2019.